Drive methandriol + boldenone undecylenate

However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. [3]

Like other AAS, boldenone is an agonist of the androgen receptor (AR). [5] The activity of boldenone is mainly anabolic , with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys. [6] Boldenone was synthesized in an attempt to create a long-acting injectable metandienone , for androgen deficiency disorders. Boldenone acts similar to metandienone with fewer adverse androgenic effects. [ medical citation needed ] Although commonly compared to nandrolone , boldenone lacks progesterone receptor interaction and associated progestogenic side effects.

Drive methandriol + boldenone undecylenate

drive methandriol + boldenone undecylenate


drive methandriol + boldenone undecylenatedrive methandriol + boldenone undecylenatedrive methandriol + boldenone undecylenatedrive methandriol + boldenone undecylenate